Supporting information for Dzioyeva et al. (2003) Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0830111100
Fig. 5.
Short GABABR1 dsRNA attenuates the behavioral effects of 3-APMPA. Four days prior to drug experiments, the flies were injected with vehicle (Veh; non-dsRNA control), 100 ng/μl dsRNA-I (against human 5-LOX; control dsRNA), or 100 ng/μl dsRNA-II (against GABABR1). (A) The reduction of locomotor activity by 3-APMPA (10 pmol per fly) was significantly less pronounced in flies pretreated with dsRNA-II (*, P £ 0.05; Scheffe’s test; mean ± SEM; n = 17 per group). (B) Also, the number of 3-APMPA-triggered catatonia-like episodes was decreased in flies pretreated with GABABR1 dsRNA (*, P £ 0.001; Scheffe’s test; mean ± SEM; n = 17 per group).